SCHEMBL5137555

SCHEMBL5137555

CCCCn1c(CN(Cc2ccccc2)Cc2ccc(OC)c(C(=O)OC)c2)cnc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
BCHE P06276 3/20 0.38
ACHE P22303 3/20 0.38
PTPN1 P18031 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
HPGD P15428 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.36
AGTR1 P30556 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135282 0.91 ALDH1A1 (0.37) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL5134721 0.88 SMN1; SMN2 (0.39) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL4764384 0.88 MEN1 (0.44) LMNAMEN1KMT2APOLBTDP1
SCHEMBL5134636 0.87 AGTR1 (0.46) ALDH1A1MAPTAGTR1
SCHEMBL5153260 0.85 MEN1 (0.38) LMNAMEN1KMT2APOLBTDP1
SCHEMBL5135870 0.85 MEP1B (0.38) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL5137530 0.85 ALDH1A1 (0.38) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL5136872 0.84 LMNA (0.40) HTTALDH1A1LMNAMEN1KMT2A
SCHEMBL5135023 0.83 AGTR1 (0.45) SMN1; SMN2ACHEMAPTAGTR1
SCHEMBL5135275 0.83 LDHA (0.42) LTB4R2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed